---
title: Randomized Trial on the Effect of an Oral Spleen Tyrosine Kinase Inhibitor
  in the Treatment of IgA Nephropathy
date: '2023-12-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38106605/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231218170853&v=2.18.0
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: There was a trend toward reduction in proteinuria with
  fostamatinib in a predefined analysis of high risk patients with IgAN despite maximal
  care, as defined by baseline UPCR greater than 1000 mg/g. Further study may be ...'
disable_comments: true
---
CONCLUSIONS: There was a trend toward reduction in proteinuria with fostamatinib in a predefined analysis of high risk patients with IgAN despite maximal care, as defined by baseline UPCR greater than 1000 mg/g. Further study may be ...